Thermo Fisher Scientific Inc. reported a revenue increase of 4% for the fiscal year ended December 31, 2025, reaching $44.56 billion, compared to $42.88 billion in 2024. The company's GAAP operating income also rose by 6% to $7.75 billion, resulting in an operating income margin of 17.4%, up from 17.1% in the previous year. Diluted earnings per share increased by 7% to $17.74, reflecting the company's ongoing efforts to enhance profitability through productivity improvements and strategic investments.
The company experienced notable changes in its revenue streams, with growth in the pharmaceutical and biotech markets driven by increased customer demand, although this was partially offset by a decline in demand for COVID-19-related products. The academic and government markets saw a revenue decline due to customer hesitancy amid economic uncertainties, particularly in the U.S. and China. In contrast, the industrial and applied markets reported revenue growth, while the diagnostics and healthcare market remained flat. Geographic revenue contributions were led by North America, Europe, and Asia-Pacific, with a decline noted in China.
Strategically, Thermo Fisher made significant acquisitions, including the purchase of Olink Holding AB in July 2024, enhancing its capabilities in the proteomics market, and the acquisition of a filtration and separation business from Solventum Corporation in September 2025, which bolstered its bioproduction offerings. The company also announced plans to acquire Clario Holdings, Inc. for approximately $8.875 billion, expected to close in mid-2026, further expanding its Laboratory Products and Biopharma Services segment.
Operationally, Thermo Fisher employed approximately 125,000 individuals globally as of December 31, 2025, with a focus on enhancing employee engagement and development. The company reported a strong cash position, with cash and cash equivalents totaling $9.85 billion, up from $4.01 billion in 2024. The company’s total debt increased to $39.38 billion, reflecting its ongoing investment strategy and acquisitions. The company anticipates continued growth in 2026, driven by its focus on high-impact innovation and expanding its commercial capabilities.
Looking ahead, Thermo Fisher expects its GAAP effective tax rate for 2026 to be between 7% and 9%, with an adjusted tax rate of approximately 11.5%. The company remains committed to its growth strategy, emphasizing innovation and customer partnerships, while navigating the challenges posed by market conditions and regulatory environments.
About THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a global leader in serving science, providing innovative products and services across four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings include reagents, instruments, diagnostics, and contract services for customers in healthcare, research, pharma, and industrial markets, supporting innovation, productivity, and quality in scientific and medical fields.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.